AGENDA

Uniform Formulary Beneficiary Advisory Panel (UF BAP)
For the May 2026 Department of War Pharmacy and Therapeutics Committee Meeting
June 24, 2026 at 10:00 AM Eastern Daylight Time

Day #3 Meeting

The UF BAP meetings occurring on June 22-24, 2026, will include information presented at the DoW Pharmacy and Therapeutics (P&T) Committee meetings from February 2025, May 2025, Addendum to May 2025 held July 10, 2025, August 2025, November 2025, Addendum to November 2025 held January 16, 2026, February 2026 and May 2026. The information presented on June 22 (Day #1) will include the recommendations from the February 2025 (presented in the morning) and May 2025 and the July 10 Addendum (presented in the afternoon) P&T meetings. The information presented on June 23 (Day #2) will include the recommendations from August 2025 (presented in the morning) and November 2025, Addendum to November 2025 held January 16,2026 and February 2026 (presented in the afternoon) P&T meetings. The information presented on June 24(Day #3) will include the information presented at the May 2026 P&T meeting.

Administrative Meeting 9:00 AM – 9:15 AM Eastern Daylight Time

<u>Information from the May 2026 DoW P&T Meeting</u>

- **General session starts at 10:00 AM Eastern Daylight Time**
- **Roll Call**
- **Therapeutic Class Reviews**

  Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effectiveness analyses along with the DoW P&T Committee recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

  The DoW P&T Committee made recommendations for the following drugs/drug classes during the May 2026 meeting.

  - **Drug Class Reviews**
    - *Antihemophilic Agents: Non-Factor Agents Subclass*
    - *Leukemia and Lymphoma Agents: Breakpoint cluster (BCR)-Ableson (ABL) Tyrosine Kinase Inhibitors (TKIs) Subclass*
  - **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
    - *aficamten (Myqorzo) – Miscellaneous Cardiovascular Agent for obstructive hypertrophic cardiomyopathy*
    - *amlodipine powder for oral solution (Sdamlo) – Calcium Channel Blocking*

Agents

- *copper histidinate injection (Zycubo) – Electrolyte-Mineral-Trace Element for Menkes Disease*
- *desmopressin acetate 0.05 mg/mL oral solution (Desmoda) – Miscellaneous Endocrine Agent for Diabetes Insipidus*
- *doxecitine /doxribtimine 2 gram packet for oral solution (Kygevvi) – Miscellaneous Metabolic Agent replacement enzyme for thymidine kinase 2 deficiency*
- *etripamil nasal spray (Cardamyst) – Calcium Channel Blocker*
- *icotrokinra (Icotyde) – Targeted Immunomodulatory Biologics (TIBs): Interleukin-23 (IL-23) inhibitor for plaque psoriasis*
- *lerodalcibep-liga injection (Lerochol) – Antilipidemic-1 Agent; Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor*
- *lisdexamfetamine dimesylate 10 mg/mL oral solution (Arynta) – Attention Deficit Hyperactivity Disorder (ADHD) Agent: Stimulant*
- *methocarbamol 750 mg/5 mL oral suspension (Atmeksi) – Skeletal Muscle Relaxants and Combinations*
- *navepegritide powder for injection (Yuviwel) – Growth Stimulating Agent for achondroplasia*
- *orforglipron (Foundayo) – Metabolic Dysfunction Agents: Weight Loss*
- *pegzilarginase-nbln injection (Loargys) – Miscellaneous Metabolic Agent for hyperargininemia*
- *pivmecillinam (Pivya)– Beta Lactam Antibiotic for urinary tract infections*
- *tizanidine 2 mg/5 mL oral solution (Ontralfy) – Skeletal Muscle Relaxants and Combinations*
- *tocilizumab-anoh injection syringe (Avtozma) – Targeted Immunomodulatory Biologics (TIBs), Interleukin-6 (IL-6) inhibitor; Actemra biosimilar*

➢ **Utilization Management Issues**

- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Antihistamine-1: Second Generation and Combinations—desloratadine solution*
  - *Corticosteroids-Immune Modulators: Low Potency—hydrocortisone rectal suppository (Anusol HC, Proctocort)*
  - *Diabetes Non-Insulin: Biguanides—metformin 625 mg IR tablet*
  - *Histamine 2 (H2) Blockers and Other Antiulcer Agents—ranitidine*
  - *Pain Agents: Non-Steroidal Anti-inflammatory Drugs (NSAIDs)—*

ibuprofen 300 mg tablets

- *Pain Agents: NSAIDs—ketoprofen (Orudis) 75 mg capsule*
- *Skeletal Muscle Relaxants and Combinations—tizanidine 8 mg capsule*

- **New PA Criteria**
  - *Skeletal Muscle Relaxants and Combinations—metaxalone 640 mg tablet*
  - *Beta Blockers and Hydrochlorothiazide Combinations— metoprolol tartrate 12.5 mg IR tablet tablets*
  - *Gastrointestinal-2 Agents—sodium phenylbutyrate packets for oral suspension (Olpruva), sodium phenylbutyrate oral pellets (Pheburane), and glycerol phenylbutyrate oral liquid (Ravicti)*
  - *Pulmonary-1 Agents: Short-acting Beta Agonists—budesonide/albuterol (Airsupra)*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Antibiotics—gepotidacin (Blujepa)*
  - *Atopy: IL-13, IL-31—dupilumab (Dupixent)*
  - *Breast Cancer Agents: PARP Inhibitors—rucaparib (Rubraca)*
  - *Electrolyte-Mineral-Trace Element Replacement—ferric maltol (Accrufer)*
  - *Gynecological Agents Miscellaneous—flibanserin (Addyi)*
  - *Lung Cancer: HER2+—zongertinib (Hernexeos)*
  - *Metabolic Agents Miscellaneous—pegvaliase-pqpz (Palynziq)*
  - *Oncological Agents—niraparib/abiraterone acetate (Akeega)*
  - *Targeted Immunomodulatory Biologics (TIBs)—deucravacitinib (Sotyktu)*
- **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
  - *Endocrine Agents Miscellaneous—octreotide (Mycapssa)*
  - *Hematological Agents—avacopan (Tavneos)*
  - *Miscellaneous Cardiovascular Agents for obstructive hypertrophic cardiomyopathy (HCM)—mavacamten (Camzyos)*
  - *Pulmonary-1 Agents: Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis*
    - *nerandomilast (Jascayd)*
    - *nintedanib (Ofev)*
    - *pirfenidone (Esbriet) PA removal*
  - *TIBs: Tumor Necrosis Factor Inhibitors—etanercept (Enbrel)*
  - *TIBs: IL-1, IL-6, CTLA-4—anakinra (Kineret)*

- *Updating the Automated Specialist Bypass Implementation*

- **Panel Discussions**

  The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoW P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.

- **Adjournment**